To clearly observe the complexity of mechanisms involved in tumor response to PD-1 blockade among different tumor types, Taube et al. 11have explored the predictive value of PD-L1 expression and multiple immune biomarkers of tumor microenvironment in nivolumab-treated patients. This evidence concerns the gene CD274 and neoplasm.